Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.
de Leeuw ALMP, Giralt J, Tao Y, Benavente S, Nguyen TF, Hoebers FJP, Hoeben A, Terhaard CHJ, Lee LW, Friesland S, Steenbakkers RJHM, Tans L, van Kranen SR, van de Kamer JB, Bartelink H, Rasch CRN, Sonke JJ, Hamming-Vrieze O. de Leeuw ALMP, et al. Among authors: rasch crn. Radiother Oncol. 2024 Nov 9;202:110612. doi: 10.1016/j.radonc.2024.110612. Online ahead of print. Radiother Oncol. 2024. PMID: 39522824
A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
de Leeuw ALMP, Giralt J, Tao Y, Benavente S, France Nguyen TV, Hoebers FJP, Hoeben A, Terhaard CHJ, Wai Lee L, Friesland S, Steenbakkers RJHM, Tans L, Heukelom J, Kayembe MT, van Kranen SR, Bartelink H, Rasch CRN, Sonke JJ, Hamming-Vrieze O. de Leeuw ALMP, et al. Among authors: rasch crn. Radiother Oncol. 2024 Jul;196:110281. doi: 10.1016/j.radonc.2024.110281. Epub 2024 Apr 16. Radiother Oncol. 2024. PMID: 38636708 Clinical Trial.
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C. Heukelom J, et al. BMC Cancer. 2013 Feb 22;13:84. doi: 10.1186/1471-2407-13-84. BMC Cancer. 2013. PMID: 23433435 Free PMC article. Clinical Trial.
Adaptive Radiotherapy for Anatomical Changes.
Sonke JJ, Aznar M, Rasch C. Sonke JJ, et al. Semin Radiat Oncol. 2019 Jul;29(3):245-257. doi: 10.1016/j.semradonc.2019.02.007. Semin Radiat Oncol. 2019. PMID: 31027642 Review.
Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.
Heukelom J, Kantor ME, Mohamed ASR, Elhalawani H, Kocak-Uzel E, Lin T, Yang J, Aristophanous M, Rasch CR, Fuller CD, Sonke JJ. Heukelom J, et al. Radiother Oncol. 2020 Jan;142:100-106. doi: 10.1016/j.radonc.2019.07.034. Epub 2019 Aug 17. Radiother Oncol. 2020. PMID: 31431381 Free PMC article.
170 results